#151408

Anti-BCL2 [bcl-2/90]

Cat. #151408

Anti-BCL2 [bcl-2/90]

Cat. #: 151408

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Bcl2

Class: Monoclonal

Application: IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jacqueline Cordell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-BCL2 [bcl-2/90]
  • Research fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
  • Clone: bcl-2/90
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB
  • Description: The pro-survival protein BCL2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Damage to the Bcl-2 gene has been identified as a cause of a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukemia, and lung cancer, and a possible cause of schizophrenia and autoimmunity. It is also a cause of resistance to cancer treatments.
  • Immunogen: Synthetic peptide of amino acids 41-54 of human bcl-2 oncoprotein
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Bcl2
  • Target background: The pro-survival protein BCL2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Damage to the Bcl-2 gene has been identified as a cause of a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukemia, and lung cancer, and a possible cause of schizophrenia and autoimmunity. It is also a cause of resistance to cancer treatments.

Applications

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C